Great Point Partners (GPP), a US-based healthcare-focused private investment firm, has acquired a majority stake in Lenis Group, a Slovenian-based full-service regional commercialisation and distribution partner for niche and specialty Rx medicines.
Founded in 2008, Lenis has built a reputation as a partner to biotechnology and pharmaceutical companies across the Central and Eastern Europe (CEE) region, covering the product lifecycle – from early access and pre-launch, through launch and growth, to mature lifecycle management.
In local markets, it is an important stakeholder in ensuring the continuous availability of critical therapies, working in close collaboration with healthcare institutions and professionals, regulatory authorities, NGOs and patient organisations.
“Every country deserves a strong and reliable pharmaceutical supply chain, and there is no company with the track record, expertise and unparalleled quality and compliance standards in the CEE that matches that of the Lenis Group,” said David Slattery, GPP’s principal and head of the firm’s London office.
GPP’s investment marks a new chapter of growth and expansion for Lenis. Resources are being committed to the company’s regional expansion and to strengthen its senior leadership, including with the appointment of Michel Vounatsos, formerly CEO of Biogen, as chairman. Lenis’ existing management team will remain with the business on a day-to-day basis.
“When selecting a partner for this next stage in our development, we sought a group that could bring true value and share the support of the mission that we are deeply committed to,” said Branko Huč, founder of Lenis Group. “Great Point Partners’ unrivalled healthcare expertise made them the clear choice.”
Huč retains a minority shareholding.
Financial advisors: Andersen (Katarina Kresal, Kaja Deutschbauer, Janja Ovsenik)
Legal advisors: Stradley Ronon (Lisa Jacobs, Dean Krishna, David Winkowski, Kate Pfingsten); Odvetniška pisarna Jerovšek-Malis (Rok Jerovšek)